Overview

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

Status:
Not yet recruiting

Trial end date:
2023-03-15

Target enrollment:

Participant gender:

Summary

Evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray for amelioration of signs and symptoms of dry eye disease in subjects following laser-assisted in situ keratomileusis (LASIK).

Phase:

Phase 3

Details

Lead Sponsor:

Vance Thompson Vision ND

Treatments:

Varenicline